Nearly two years after the Covid-19 pandemic prompted remote inspections of pharmaceutical production plants, an international coalition of regulators is recommending the approach be used to complement on-site visits for the foreseeable future.
Although remote inspections posed various limitations on medicines regulators in recent months, the strategy also yielded some productive insights, such as the use of digital technology to gather electronic clinical trial data and additional intelligence about manufacturing sites, according to a new “reflection paper” from the International Coalition of Medicine Regulatory Authorities.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
